It can be measured to help in tumour classification to aid treatment. FBP is over-expressed (20-80 fold) in more than 90% of ovarian and endometrial cancers, as well as 20-50% of breast, lung, colorectal, and renal cell carcinomas. FBP has very limited tissue distribution and expression in non-malignant tissue, making it a good immunotherapy target.
- "The role of folate receptor a in cancer development, progression and treatment: Cause, consequence or innocent bystander?". Int. J. Cancer. 119 (2): 243–50. 2006. doi:10.1002/ijc.21712. PMID 16453285.
- "Folate-binding Protein Is a Marker for Ovarian Cancer". 1991.
|This biochemistry article is a stub. You can help Wikipedia by expanding it.|